Beijing,
A Covid-19 vaccine candidate developed by a Beijing unit of China National Biotec Group (CNBG) has shown positive results in early human trials, the company said on Sunday.
According to the company, all 1,120 volunteers in the phase-1 and phase-2 clinical trials produced high-titer antibodies against Covid-19 after accepting two doses of the vaccine, the Global Times reported.
The clinical trials which started on April 27 in Shangqiu county in China’s Henan province have shown the vaccine to be effective and safe, said CNBG.
The trials were designed as randomised, double-blind and placebo-controlled studies.
This is not the first Covid-19 vaccine candidate from CNBG, which is affiliated to the state-owned China National Pharmaceutical Group (Sinopharm).
